Abstract
Osteoporosis is an important cause of morbidity in beta-thalassemia patients. Bisphosphonates have been recently used for the treatment of osteoporosis in beta-thalassemia. This study is a prospective quasi-experimental study to assess the efficacy and safety of zoledronic acid in thalassemics with osteoporosis. Eighteen thalassemia patients with osteoporosis were given zoledronic acid 4 mg intravenously every 3 months over a period of 12 months. The efficacy of treatment was assessed by measuring (BMD) at the lumbar spine, femoral neck, and hip at baseline, 6, and 12 months. Z-score was used to measure the BMD. Other medical assessments included markers of bone formation and resorption (bone alkaline phosphatase (BAP), osteocalcin (OC), and urinary deoxypyridinoline), and the assessment of pain score, analgesic score, and performance score. Ten thalassemic osteoporotic patients were followed up only with serial BMDs as controls. Both groups had no significant difference with respect to age, gender, and baseline BMD. Patients taking zoledronic acid had a significant increase in their lumbar spine, femoral neck, trochanter, and total hip BMD measurements over the 12-month period. Patients in the control group did not have any significant change in BMD measurements. There was a significant change in the levels of OC and BAP over the 12-month follow-up period. There was also a significant decrease in the number of painful sites experienced by the patients. Treatment of thalassemic osteoporotic patients with zoledronic acid is very effective in increasing BMD at the lumbar spine and hip and in reducing pain; it is also well-tolerated.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Olivieri NF (1999) The beta-thalassemias. N Engl J Med 341:99–109
Voskaridou E, Kyrtsonis MC, Terpos E, Skordili M, Theodoropoulos I, Bergele A, Diamanti E, Kalovidouris A, Loutradi A, Loukopoulos D (2001) Bone resorption is increased in young adults with thalassaemia major. Br J Haematol 112:36–41
Wonke B (1998) Bone disease in beta-thalassaemia major. Br J Haematol 103:897–901
Voskaridou E, Terpos E (2004) New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 127:127–139
Lasco A, Morabito N, Gaudio A, Buemi M, Wasniewska M, Frisina N (2001) Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporos Int 12:570–575
Giardina PJ, Schneider R, Lesser M, Simmons B, Rodriguez A, Gertner J (1995) In: Ando S et al (eds) Endocrine disorders in thalassaemia. Abnormal bone metabolism in thalassaemia. Springer, Berlin Heidelberg New York, pp 39–46
Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A, Prescott E, Hoffbrand AV, Wonke B (1998) High prevalence of low bone mass in thalassaemia major. Br J Haematol 103:911–915
Abdollah Shamshirsaz A, Bekheirnia MR, Kamgar M, Pourzahedgilani N, Bouzari N, Habibzadeh M, Hashemi R, Shamshirsaz AA, Aghakhani S, Homayoun H, Larijani B (2003) Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran. BMC Endocrine Disorders 3:4
Fleisch H (1998) Bisphosphonates: mechanisms of action. Endocr Rev 19:80–100
Perifanis V, Vyzantiadis T, Vakalopoulou S, Tziomalos K, Garypidou V, Athanassiou-Metaxa M, Harsoulis F (2004) Treatment of beta-thalassaemia-associated osteoporosis with zoledronic acid. Br J Haematol 125:91–92
World Health Organization Study Group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO technical report series 843. WHO, Geneva
Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS (2004) Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 20:309–318
Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A, Prescott E, Hoffbrand AV, Wonke B (1998) High incidence of osteoporosis in thalassaemia major. J Pediatr Endocrinol Metab 11(Suppl 3):975–977
Brown JP, Josse RG; Scientific Advisory Council of the Osteoporosis Society of Canada (2002) 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167(Suppl 10):S1–S34
Theriault RL (2003) Zoledronic acid (Zometa) use in bone disease. Expert Review of Anticancer Therapy 3:157–166
Morabito N, Lasco A, Gaudio A, Crisafulli A, Di Pietro C, Meo A, Frisina N (2002) Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int 13:644–649
Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A, Loukopoulos D (2003) Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol 123:730–737
Pennisi P, Pizzarelli G, Spina M, Riccobene S, Fiore CE (2003) Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis. J Bone Miner Metab 21:402–408
Acknowledgements
The authors would like to thank Novartis Pharma Services for the grant that was provided to support this study.
Approval of the ethical committee in the American University of Beirut-Medical Center and the Chronic Care Center was obtained before the initiation of the study.
The authors have no financial relationship with Novartis Pharma Services.
The authors state that they have had full control of all primary data. We agree to allow the journal to review our data if requested.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Otrock, Z.K., Azar, S.T., Shamseddeen, W.A. et al. Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial. Ann Hematol 85, 605–609 (2006). https://doi.org/10.1007/s00277-006-0136-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-006-0136-y